Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TACR3 | P29371 | 10/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PTGFR | P43088 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 4/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013005 | 0.85 | TACR3 (0.59) | CYP2D6CYP2C19TACR3PDE10ATSHR | |
| SCHEMBL2053743 | 0.81 | TACR3 (0.58) | CYP2D6CYP2C19TACR3DHODHPDE10A | |
| SCHEMBL4993354 | 0.80 | LMNA (0.47) | TACR3PTGFRPDE10ATSHRLMNA | |
| SCHEMBL4984967 | 0.80 | LMNA (0.47) | TACR3PTGFRPDE10ATSHRLMNA | |
| SCHEMBL1581556 | 0.78 | CYP2D6 (1.00) | CYP2D6CYP2C19TACR3ALDH1A1GAA | |
| SCHEMBL8249659 | 0.77 | PDE10A (0.59) | CYP2C19TACR3ALDH1A1CYP2C9PTGFR | |
| Hydrochloric Acid SCHEMBL3326324 | 0.77 | CYP2D6 (0.97) | CYP2D6CYP2C19TACR3ALDH1A1GAA | |
| SCHEMBL7686463 | 0.76 | TSHR (0.56) | CYP2C19TACR3ALDH1A1CYP2C9PTGFR | |
| SCHEMBL7686462 | 0.76 | TSHR (0.56) | CYP2C19TACR3ALDH1A1CYP2C9PTGFR | |
| SCHEMBL8190145 | 0.75 | TACR3 (0.74) | CYP2D6CYP2C19TACR3ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964733-B2 | to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc. | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | MSR1, KCNQ3, KCNA3 | CYP2D6 384/4885CYP2C19 736/4885TACR3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.